Literature DB >> 7355741

Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation.

N D Vlachakis, L Aledort.   

Abstract

The effects of propranolol on blood pressure, plasma catecholamine concentration and platelet aggregation were examined in 16 patients with uncomplicated primary hypertension. The patients were studied at rest, during isometric handrip stress and 48 hours after sudden discontinuation of propranolol therapy. Plasma catecholamine concentration and platelet aggregation studies were also carried out in 11 age-matched normotensive and healthy subjects at rest. Plasma catecholamine concentration and platelet aggregation were greater in the hypertensive than in the normotensive subjects, but the difference reached statistical significance for aggregation only. Exercise significantly increased catecholamines and platelet aggregability. The administration of propranolol (240 mg/day) produced a significant decrease in systolic and diastolic blood pressue and in aggregation (the percent of light transmission at 1 microM adenosine diphosphate, at rest) and a significant increase in catecholamine concentration. However, propranolol did not prevent the changes in all these variables with exercise. The abrupt discontinuation of propranolol was not associated with any subjective or objective untoward cardiovascular effect or abnormal changes in plasma catecholamines. However, in some patients the platelet aggregation studies demonstrated a hyperaggregable state, which may be due to a state of supersensitivity of platelets to circulating catecholamines.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7355741     DOI: 10.1016/0002-9149(80)90653-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

2.  Antiplatelet effects of oral diltiazem, propranolol, and their combination.

Authors:  M E Ring; J J Corrigan; P E Fenster
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

Review 3.  The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs.

Authors:  B N Prichard; R J Walden
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  Aggregation, membrane potential, and transport in platelets of spontaneously hypertensive rats.

Authors:  G M Kravtsov; S N Orlov; Y V Postnov
Journal:  Pflugers Arch       Date:  1984-11       Impact factor: 3.657

5.  Prolonged platelet activation in individuals with elevated blood pressure in response to a moderate exercise challenge.

Authors:  Suzi Hong; Karen A Adler; Roland Von Känel; Judy Nordberg; Michael G Ziegler; Paul J Mills
Journal:  Psychophysiology       Date:  2009-01-26       Impact factor: 4.016

6.  [Predictor function of hemorheologic parameters with reference to the incidence of manifest circulatory disorders: Concept of the Aachen study].

Authors:  H Kiesewetter; F Jung; K H Ladwig; E Waterloh; P Roebruck; R Schneider; G Kotitschke; R Bach
Journal:  Klin Wochenschr       Date:  1986-07-15

Review 7.  Blood platelets in human essential hypertension.

Authors:  F De Clerck
Journal:  Agents Actions       Date:  1986-08

8.  Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol.

Authors:  A Markel; J G Brook; Y Levy; M Aviram; M B Youdim
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 9.  Alpha- and beta-blockade in angina pectoris.

Authors:  S H Taylor
Journal:  Drugs       Date:  1984       Impact factor: 9.546

10.  Effects of propranolol in vitro and in vivo on platelet function and thromboxane formation in normal volunteers.

Authors:  W Siess; R Lorenz; P Roth; P C Weber
Journal:  Agents Actions       Date:  1983-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.